Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.33 |
| ▸ | GCG | P01275 | 7/20 | 0.32 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401014 | 0.98 | NAMPT (0.34) | NAMPTRCE1L3MBTL1JAK1IDH1 | |
| SCHEMBL3399873 | 0.94 | NAMPT (0.35) | NAMPTGCGRCE1PDE7A | |
| SCHEMBL718563 | 0.92 | NAMPT (0.34) | NAMPTRCE1L3MBTL1JAK1IDH1 | |
| SCHEMBL720850 | 0.89 | GCGR (0.36) | NAMPTGCGL3MBTL1TSHRMEN1 | |
| SCHEMBL716694 | 0.88 | NAMPT (0.35) | NAMPTGCGRCE1PDE7A | |
| SCHEMBL717719 | 0.86 | TP53 (0.36) | NAMPTL3MBTL1IDH1TSHRMEN1 | |
| SCHEMBL722172 | 0.86 | RCE1 (0.41) | NAMPTGCGRCE1L3MBTL1JAK1 | |
| SCHEMBL721611 | 0.85 | RCE1 (0.37) | NAMPTGCGRCE1L3MBTL1PDE7A | |
| SCHEMBL716869 | 0.84 | MEN1 (0.41) | GCGPDE7AMEN1KMT2A | |
| SCHEMBL719238 | 0.84 | RCE1 (0.41) | NAMPTRCE1L3MBTL1JAK1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | NAMPT 69/4885GCG 35/4885RCE1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.